In the last trading session, 2.09 million Nektar Therapeutics (NASDAQ:NKTR) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $0.91 changed hands at $0.01 or 1.39% during last session, the market valuation stood at $167.73M. NKTR’s last price was a discount, traded about -112.09% off its 52-week high of $1.93. The share price had its 52-week low at $0.65, which suggests the last value was 28.57% up since then. When we look at Nektar Therapeutics’s average trading volume, we note the 10-day average is 1.54 million shares, with the 3-month average coming to 2.02 million.
Analysts gave the Nektar Therapeutics (NKTR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.11. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NKTR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Nektar Therapeutics’s EPS for the current quarter is expected to be -0.18.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR was in green as seen at the end of in last trading. With action 10.89%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -2.23%, with the 5-day performance at 10.89% in the green. However, in the 30-day time frame, Nektar Therapeutics (NASDAQ:NKTR) is 1.96% up. Looking at the short shares, we see there were 6.62 million shares sold at short interest cover period of 2.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 95.08% from its current market value. According to analyst projections, NKTR’s forecast low is 6 with 24 as the target high. To hit the forecast high, the stock’s price needs a -2537.36% plunge from its current level, while the stock would need to soar -559.34% for it to hit the projected low.
Nektar Therapeutics (NKTR) estimates and forecasts
Year-over-year growth is forecast to reach -36.41% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 15.61M. 9 analysts are of the opinion that Nektar Therapeutics’s revenue for the current quarter will be 15.7M. The company’s revenue for the corresponding quarters a year ago was 21.64M and 23.49M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -27.88%. The estimates for the next quarter sales put growth at -33.15%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 25.49%. The 2025 estimates are for Nektar Therapeutics earnings to decrease by -8.45%, but the outlook for the next 5-year period is at -11.68% per year.
NKTR Dividends
Nektar Therapeutics is expected to release its next quarterly earnings report on 2025-Mar-11.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.27% of Nektar Therapeutics shares while 72.51% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 73.45%. There are 72.51% institutions holding the Nektar Therapeutics stock share, with DEEP TRACK CAPITAL, LP the top institutional holder. As of 2024-06-30, the company held 8.5599% of the shares, roughly 17.88 million NKTR shares worth $22.17 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30.
